Related Experiment Video
Updated: Apr 1, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
A French National Survey on Clotting Disorders in Mastocytosis
Ana B Carvalhosa1, Achille Aouba, Gandhi Damaj
1From the French Reference Centre for Mastocytosis (CEREMAST), Necker Children's Hospital, Assistance Publique - Hôpitaux de Paris (APHP), France (ABC, GD, DC, CB, SB, LF, OL, OH, M-OC); Haemostasis and Thrombosis Unit, Haemophilia Clinic, Division of Haematology, St-Luc University Hospital, Brussels, Belgium (ABC, CH); Department of Internal Medicine, Caen University Hospital, France (AA); Department of Haematology, Caen University Hospital, France (GD); Department of Pathology, Necker Children's Hospital, APHP, France (DC); Department of Biological Haematology, Necker Children's Hospital, APHP, France (CB); Department of Haematology and Cell Therapy, Tours University Hospital, France (EG); Department of Internal and Vascular Medicine, Lyon Sud University Hospital, France (SD, ID); Department of Internal Medicine, Saint-Etienne University Hospital, France (PC); Department of Internal Medicine, Cochin Hospital, APHP, France (NC-C); Department of Internal Medicine, Lille University Hospital, France (DL); Infectious Diseases Department, Necker Children's Hospital, APHP, France (BP, OL); Department of Dermatology, Tenon University Hospital, APHP, France (SB); Department of Haematology, Necker Children's Hospital, APHP, France (LF, OH, M-OC); and Sorbonne Paris Cité, Paris Descartes University, Imagine Institute, Paris, France (LF, OL, OH, M-OC).
Insights
Mastocytosis patients can experience clotting issues due to mast cell degranulation and infiltration. Steroids effectively manage these bleeding disorders by inhibiting mast cell activity, unlike traditional treatments.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Mastocytosis involves clonal mast cell proliferation, organ infiltration, and degranulation.
- Clotting abnormalities are observed in some mastocytosis patients but are poorly understood.
- Mast cell mediators like heparin and tryptase can impact hemostasis.
Purpose of the Study:
- To investigate the characteristics and management of clotting abnormalities in mastocytosis patients.
- To identify the underlying mechanisms of hemostatic disorders in mastocytosis.
- To evaluate the efficacy of different management strategies for bleeding complications.
Main Methods:
- Retrospective analysis of 14 adult mastocytosis patients with clotting abnormalities.
- Utilized the French Reference Centre for Mastocytosis database.
- Assessed primary and secondary hemostasis disorders, bleeding characteristics, and treatment outcomes.
Main Results:
- Four patients had primary hemostasis disorders, and 10 had secondary hemostasis impairment.
- Seven patients experienced bleeds characteristic of coagulation cascade disorders (5 severe/life-threatening).
- Conventional hemostatic management was unsuccessful; steroids inhibiting mast cell activity were effective.
- Aggressive mastocytosis and increased mortality were noted in patients with secondary hemostasis disorders.
Conclusions:
- Mast cell degranulation and high tumor burden induce pro-coagulant and anti-coagulant states.
- These states lead to a spectrum of bleeding complications, from asymptomatic to life-threatening.
- Effective hemostatic control in mastocytosis is achieved through mast cell inhibitors, particularly steroids.
Abstract:
Mastocytosis is characterized by a clonal mast cell proliferation with organ infiltration and uncontrolled degranulation. Although not characteristic and poorly explained, some patients develop clotting abnormalities. We retrospectively identified patients with established diagnosis of mastocytosis and related clotting abnormalities (clinical and/or biological) using the national French Reference Centre for Mastocytosis database. From our cohort of 14 adult patients with clotting abnormalities (median age 46 years [range 26-75]), 4 had a presentation suggestive of a primary hemostasis disorder alone (by their symptoms and/or abnormal clotting tests [PFA, von Willebrand's disease [vWD] screening]) and 10 had a laboratory impairment of secondary hemostasis. Among these, 7 had bleeds characteristic of a coagulation cascade disorder (severe/life-threatening in 5 and mild in 2 patients). Clotting abnormalities were of variable severity, typically related to intense crisis of degranulation, such as anaphylactic reactions, and/or to severe organ infiltration by mast cells. Importantly, classical hemostatic management with platelet transfusion, fresh frozen plasma, or vitamin K infusions was unsuccessful, as opposed to the use of agents inhibiting mast cell activity, particularly steroids. This illustrates the crucial role of mast cell mediators such as tryptase and heparin, which interfere both with primary (mainly via inhibition of von Willebrand factor) and secondary hemostasis. There was interestingly an unusually high number of aggressive mastocytosis (particularly mast cell leukemia) and increased mortality in the group with secondary hemostasis disorders (n = 5, 36% of the whole cohort). Mast cell degranulation and/or high tumoral burden induce both specific biologic antiaggregant and anticoagulant states with a wide clinical spectrum ranging from asymptomatic to life-threatening bleeds. Hemostatic control is achieved by mast cell inhibitors such as steroids.
More Related Videos
09:46Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...